Systemic Anaplastic Large Cell Lymphoma

Systemic Anaplastic Large Cell Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

6 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1
Recruiting: 1
Ph III recruiting: 1
Growth YoY: —
Industry share: 100%
Top sponsor: Corvus Pharmaceuticals, Inc.
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02729961	Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma	withdrawn	Phase 1 / Phase 2	0	University of WashingtonOTHER	1	Oct 10, 2019	clinicaltrials

Data updated 22 days agoSource updated Oct 10, 2019source: clinicaltrials